Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: Possible molecular target for osteoarthritis therapeutic intervention

Annals of the Rheumatic Diseases

Volumn 66, Issue 12, 2007, Pages 1616-1621

  Iliopoulos, D ^b   Malizos, K N ^a   Tsezou, A ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; COLLAGENASE 3; GELATINASE B; HISTONE H3; LEPTIN; LYSINE; MESSENGER RNA; SMALL INTERFERING RNA; STROMELYSIN; TRICHOSTATIN A;

ACETYLATION; ADULT; AGED; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; ENZYME ACTIVITY; EPIGENETICS; FEMALE; GENE CONTROL; HUMAN; HUMAN CELL; HUMAN TISSUE; KNEE OSTEOARTHRITIS; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ACETYLATION; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; AZACITIDINE; BLOTTING, WESTERN; CARTILAGE, ARTICULAR; CASE-CONTROL STUDIES; CHONDROCYTES; DNA METHYLATION; DNA MODIFICATION METHYLASES; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; KNEE JOINT; LEPTIN; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OSTEOARTHRITIS; PROMOTER REGIONS (GENETICS); RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 36549024994     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.069377     Document Type: Article

References (43)

1. Mahr S, Burmester GR, Hilke D, Gobel U, Grutzkau A, Haupl T, et al. Cis- and trans-acting gene regulation is associated with osteoarthritis. Am J Hum Genet 2006;78:793-803.
2. Thomas CM, Fuller CJ, Whittles CE, Sharif M. Chondrocyte death by apoptosis is associated with cartilage matrix degradation. Osteo Cart 2006;19 Jul [Epub ahead of print].
3. Eleswarapu SV, Leipzig ND, Athanasiou KA. Gene expression of single articular chondrocytes. Cell Tissue Res 2006;31 Aug [Epub ahead of print].
4. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006;11:529-43.
5. Forsyth CB, Cole A, Murphy G, Bienias JL, Im HJ, Loeser RF Jr. Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli. J Gerontol A Biol Sci Med Sci 2005;60:1118-24.
6. Meng J, Ma X, Ma D, Xu C. Microarray analysis of differential gene expression in temporomandibular joint condylar cartilage after experimentally induced osteoarthritis. Osteo Cart 2005;13:1115-25.
7. Aigner T, Zien A, Hanisch D, Zimmer R. Gene expression in chondrocytes assessed with use of microarrays. J Bone Joint Surg Am 2003;85A(Suppl 2):117-23.
8. Serman A, Vlahovic M, Serman L, Bulic-Jakus F. DNA methylation as a regulatory mechanism for gene expression in mammals. Coll Antropol 2006;30:665-71.
9. Villar-Garea A, Imhof A. The analysis of histone modifications. Biochim Biophys Acta, 2006;26 Aug [Epub ahead of print].
10. Schob H, Grossniklaus U. The first high-resolution DNA "methylome". Cell 2006;126:1025-8.
11. Fukuda H, Sano N, Muto S, Horikoshi M. Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct Genomic Proteomic 2006;5:190-208.
12. Lu O, Oiu X, Hu N, Wen H, Su Y, Richardson BC. Epigenetics, disease and therapeytic interventions. Ageing Res Rev 2006;5:449-67.
13. Bhalla Kn. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-93.
14. Stebbing J, Bower M, Syed N, Smith P, Yu Y, Crook T. Epigenetics:an emerging technology in the diagnosis and treatment of cancer. Pharmacogenomics 2006;7:747-57.
15. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematologic malignancies. Blood Rev 2006;20:1-13.
16. Roach MI, Algner T. DNA methylation in osteoarthritic chondrocytes: a new molecular target. Osteo Cart 2006;12 Aug [Epub ahead of print].
17. Roach MI, Yamanda N, Cheung KS, Tilley S, Clarke NM, Oreffo RO, et al. Association between the abnormal expression of matrix degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions. Arthr Rheum 2005;52:3110-24.
18. Santos-Reboucas CB, Pimentel MM. Implication of abnormal epigenetic patterns for human diseases. Eur J Hum Genet 2006;18 Oct [Epub ahead of print].
19. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;72:425-32.
20. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000;92:73-8.
21. Kume K, Satomura K, Nishisho S, Kitaoka E, Yamanouchi K, Tobiume S, et al. Potential role of leptin on endochondral ossification. J Histochem Cytochem 2002;50:159-69.
22. Elefteriou F, Jong Deok Ahn, Takeda S, Starbuck M, Yang X, Liu X, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005;434:514-20.
23. Elmquist JK, Strewler GJ. Do neural signals remodel bone? Nature 2005;434:447-8.
24. Gordeladge JO, Drevon CA, Syversen U, Reseland JE. Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. J Cell Biochem 2002;85:825-36.
25. Gong DW, Bi S, Pratley RE, Weintraub BD. Genomic structure and promoter analysis of the humane obese gene. J Biol Chem 1996;271:3971-4.
26. Stoger R. In vivo methylation patterns of the leptin promoter in human and mouse. Epigenetics 2006;1:155-62.
27. Miller SG, De Vos P, Guerre-Millo M, Wong K, Herman T, Staels B, et al. The adipocyte specific transcription factor C/EBPalpa modulates human ob gene expression. Proc Natl Acad Sci USA 1996;93:5507-11.
28. Melzner I, Scott V, Dorsch K, Fischer P, Wabitsch M, Bruderlein S, et al. Leptin gene expression in human preadipocytes is switched on by maturation-induced demethylation of distinct CpGs in its proximal promoter. J Biol Chem 2002;277:45420-7.
29. Baylin SB, Esteller M, Rountree MR, Bachmann KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92.
30. Hiltunen MO, Yia-Hertuala S. DNA methylation, smooth muscle cells and atherogenesis. Arterioscler Thromb Vasc Biol 2003;23:1750-3.
31. Fernandez MP, Young MF, Sobel ME. Methylation of type II and type I collagen genes in differentiated and dedifferentiated chondrocytes. J Biol Chem 1985;260:2374-8.
32. Aoyama T, Okamoto T, Nagayama S, Nishijo K, Ishibe T, Yasura K, et al. Methylation in the core-promoter region of the chondromodulin-I gene determines the cell-specific expression by regulating the binding of transcriptional activator Sp3. J Biol Chem 2004;279:28789-97.
33. Richardson B. Impact of aging on DNA methylation. Ageing Res Rev 2003;2:245-61.
34. Richardson BC. Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J Nutr 2002;132:2401-5.
35. Gollob JA, Sciambi O, Peterson BL, Richmond T, Thoreson M, Moran K, et al. Phase I trial of sequential low dose 5′-aza- 2′deoxycytidine plus high dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006;12:4619-27.
36. Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, et al. A phase I trial of cisplatin plus decitabine, a new DNA hypomethylating agent in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 2000;1:83-91.
37. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase I study of low dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′deoxycitidine(decitabine) in hematopoietic malignancies. Blood 2004;103:1635-40.
38. Peixoto P, Lansiaux A. Histone deacetylases inhibitors:from TSA to SAHA. Bull Cancer 2006;93:27-36.
39. Secrist JP, Zhou X, Richon VM. HDAC inhibitors for the treatment of cancer. Curr Opin Invest Drugs 2003;4:1422-7.
40. Mei S, Ho AD, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer. Int J Oncol 2004;25:1509-19.
41. Zhong S, Fields CR, Su N, Pan YX, Robertson KD. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene, 2006;Oct 9[Epub ahead of print].
42. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression or genes silenced in cancer. Nature Genet 1999;21:103-7.
43. Poschl E, Fidler A, Schmidt B, Kallipolitou A, Schmidt E, Aignew T. DNA methylation is not likely to be responsible for aggregan down regulation in aged or osteoarthritic cartilage. Ann Rheum Dis 2005;64:477-80.